NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $5.00
Forecasted Upside: 390.20 %
Number of Analysts: 1
Breakdown:
0 Sell Ratings
0 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$1.02 As of 09/23/2021 01:53 PM ET

▼ -0.01 (-0.97%)

1 month | 3 months | 12 months

Get New AcelRx Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ACRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACRX

^$5.00

▲ +390.20% Upside Potential

This price target is based on 1 analysts offering 12 month price targets for AcelRx Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 390.20% upside from the last price of $1.02.

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in AcelRx Pharmaceuticals. This rating has held steady since July 2021, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

4/1/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

6/30/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

9/28/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

12/27/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

3/27/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/24/2021

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/17/2021	HC Wainwright	Lower Price Target	Buy	$7.00 ➝ $5.00	High
8/13/2020	Credit Suisse Group	Boost Price Target	Underperform	$0.69 ➝ $0.84	Low
7/20/2020	Credit Suisse Group	Downgrade	Neutral ➝ Underperform	$1.00 ➝ $0.69	High
5/12/2020	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$8.00	Low
3/17/2020	HC Wainwright	Lower Price Target	Buy	$9.00 ➝ $7.00	High
11/11/2019	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$7.00 ➝ $2.00	High
11/8/2019	HC Wainwright	Reiterated Rating	Buy	$9.00	Medium
8/5/2019	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$7.00	Medium
7/10/2019	Credit Suisse Group	Reiterated Rating	Outperform		Medium
5/9/2019	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$10.00	High
4/24/2019	B. Riley	Initiated Coverage	Buy ➝ Buy	$6.50	High
3/8/2019	LADENBURG THALM/SH SH	Set Price Target	Buy	$10.00	High
2/15/2019	Credit Suisse Group	Initiated Coverage	Outperform	$7.00	High
1/29/2019	Cantor Fitzgerald	Set Price Target	Buy	$9.00	Low
12/12/2018	HC Wainwright	Reiterated Rating	Buy	$9.00	High
12/11/2018	Oppenheimer	Reiterated Rating	Hold		High
12/11/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$9.00	High
11/6/2018	HC Wainwright	Reiterated Rating	Buy	$9.00	High
11/5/2018	Cantor Fitzgerald	Boost Price Target	Overweight	$8.00 ➝ $9.00	Low
11/2/2018	LADENBURG THALM/SH SH	Set Price Target	Buy	$10.00	High
11/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$8.00	High
10/25/2018	Cantor Fitzgerald	Set Price Target	Buy	$8.00	High
10/23/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$9.00	High
10/22/2018	Royal Bank of Canada	Set Price Target	Buy	$7.00	Medium
10/15/2018	HC Wainwright	Boost Price Target	Positive ➝ Buy	$7.00 ➝ $8.00	High
10/15/2018	Oppenheimer	Reiterated Rating	Hold		High
10/15/2018	Cantor Fitzgerald	Set Price Target	Buy	$8.00	High
10/15/2018	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$8.00	High
10/10/2018	LADENBURG THALM/SH SH	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00	High
10/9/2018	Oppenheimer	Reiterated Rating	Hold		High
10/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$6.00	Medium
10/1/2018	Cantor Fitzgerald	Set Price Target	Buy	$6.00	Medium
9/20/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$6.00	Low
8/16/2018	LADENBURG THALM/SH SH	Initiated Coverage	Buy	$7.00	High
8/7/2018	HC Wainwright	Reiterated Rating	Buy		Low
8/3/2018	Oppenheimer	Reiterated Rating	Hold		High
8/2/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$6.00	High
7/12/2018	Oppenheimer	Initiated Coverage	Hold		High
6/14/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		Medium
6/11/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$6.00	Low
10/27/2017	HC Wainwright	Reiterated Rating	Buy	$5.00	N/A
10/13/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$2.00	N/A
10/13/2017	Royal Bank of Canada	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00	N/A
10/13/2017	Jefferies Financial Group	Downgrade	Buy ➝ Hold		N/A
10/12/2017	Roth Capital	Set Price Target	Buy	$8.00	N/A
10/3/2017	HC Wainwright	Reiterated Rating	Buy	$10.00	High
8/25/2017	Royal Bank of Canada	Set Price Target	Buy	$6.00	Low
8/10/2017	Roth Capital	Reiterated Rating	Buy	$12.50	High
8/9/2017	Stifel Nicolaus	Upgrade	Hold ➝ Buy		High
8/4/2017	HC Wainwright	Reiterated Rating	Buy	$7.00	Low
8/2/2017	Roth Capital	Set Price Target	Buy	$13.00	Low
8/1/2017	Cowen	Reiterated Rating	Hold		High
7/25/2017	Piper Jaffray Companies	Set Price Target	Hold	$3.00	High
7/14/2017	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$7.00	High
3/14/2017	Stifel Nicolaus	Lower Price Target	Hold	$15.00 ➝ $14.00	Low
3/6/2017	Cowen	Reiterated Rating	Hold		N/A
3/6/2017	Roth Capital	Set Price Target	Buy	$15.00	N/A
3/3/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$6.00	N/A
12/6/2016	Roth Capital	Set Price Target	Buy	$15.00	N/A
12/5/2016	HC Wainwright	Reiterated Rating	Buy	$7.00	N/A
11/3/2016	Cowen	Reiterated Rating	Hold		N/A
11/2/2016	Roth Capital	Set Price Target	Buy	$15.00	N/A
11/2/2016	HC Wainwright	Reiterated Rating	Buy		N/A
10/15/2016	Roth Capital	Set Price Target	Buy	$15.00	N/A
10/4/2016	Jefferies Financial Group	Reiterated Rating	Buy	$7.00	N/A
9/28/2016	HC Wainwright	Reiterated Rating	Buy	$7.00	N/A

(Data available from 9/23/2016 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/25/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/27/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/26/2021

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/26/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/25/2021

11 very positive mentions
3 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

7/25/2021

13 very positive mentions
6 positive mentions
7 negative mentions
5 very negative mentions

Mentions as of

8/24/2021

2 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/23/2021

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

americanbankingnews.com
9/18/2021
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Sees Large Decline in Short Interest
nasdaq.com
9/8/2021
AcelRx Pharmaceuticals, Inc. Common Stock (ACRX)

Very Positive

finance.yahoo.com
9/18/2021
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences
finance.yahoo.com
8/26/2021
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Today's Range

Now: $1.02

$1.01

$1.04

50 Day Range

MA: $1.13

$0.93

$1.36

52 Week Range

Now: $1.02

$0.75

$2.94

Volume

3,611 shs

Average Volume

3,313,418 shs

Market Capitalization

$121.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of AcelRx Pharmaceuticals?: The following equities research analysts have issued research reports on AcelRx Pharmaceuticals in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for ACRX.
What is the current price target for AcelRx Pharmaceuticals?: 1 Wall Street analysts have set twelve-month price targets for AcelRx Pharmaceuticals in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 390.2%. HC Wainwright has the highest price target set, predicting ACRX will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for AcelRx Pharmaceuticals in the next year.
View the latest price targets for ACRX.
What is the current consensus analyst rating for AcelRx Pharmaceuticals?: AcelRx Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACRX will outperform the market and that investors should add to their positions of AcelRx Pharmaceuticals.
View the latest ratings for ACRX.
What other companies compete with AcelRx Pharmaceuticals?: Other companies that are similar to AcelRx Pharmaceuticals include Aldeyra Therapeutics, Homology Medicines, PDS Biotechnology, Cue Biopharma, Akouos, Karyopharm Therapeutics, Kezar Life Sciences, KalVista Pharmaceuticals, Marinus Pharmaceuticals, Geron, XBiotech, Eliem Therapeutics, Atossa Therapeutics, Arbutus Biopharma and Magenta Therapeutics.
How do I contact AcelRx Pharmaceuticals' investor relations team?: AcelRx Pharmaceuticals' physical mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company's listed phone number is (650) 216-3500 and its investor relations email address is [email protected] The official website for AcelRx Pharmaceuticals is www.acelrx.com.

NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for ACRX

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.69 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of AcelRx Pharmaceuticals?

What is the current price target for AcelRx Pharmaceuticals?

What is the current consensus analyst rating for AcelRx Pharmaceuticals?

What other companies compete with AcelRx Pharmaceuticals?

How do I contact AcelRx Pharmaceuticals' investor relations team?